SSAO inhibitors and use thereof

A compound of Formula (I)

• or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein:
• each X is independently Cl or F;
• p is 0, 1, 2, or 3;
• L is absent, —O—, (C1-C4) alkylene, substituted (C1-C4) alkylene, —O—(C1-C4) alkylene, substituted —O—(C1-C4) alkylene, (C1-C4) alkylene-O—, or substituted (C1-C4) alkylene-O—, wherein the substituted (C1-C4) alkylene, substituted —O—(C1-C4) alkylene, or substituted (C1-C4) alkylene-O— is substituted with one or more L1;
• each L1 is independently (C1-C4) alkyl, F, or CF3;
• or two L1, together with the atom to which they are attached, form a 3- to 5-membered cycloalkyl ring;
• each R1 is independently H, F, methyl, ethyl, or CF3;
• R2 is (C1-C4) alkyl substituted with one or more (C1-C4) alkoxy, (C1-C4) alkoxy, NR3C(O)R4, or C(O)NR3R4;
• or
• R2 is
• wherein R2 is optionally substituted with one or more R5;
• R3 is H, methyl, or ethyl;
• R4 is (C1-C4) alkyl or (C3-C10) cycloalkyl optionally substituted with one or more R8;
• or
• R3 and R4, together with atom(s) to which they are attached, form a 3- to 6-membered ring optionally comprising one additional heteroatom selected from N and O and optionally substituted with one or more R5;
• each R5 is independently (C1-C4) alkyl, (C1-C4) alkoxy, hydroxy, cyano, oxo, C(O)R7, C(O)NR7R7′, NR3C(O)R7, NR3S(O)2R4, S(O)2R4, (C1-C4) alkyl substituted with one or more hydroxy or R6, (C3-C10) cycloalkyl optionally substituted with one or more hydroxy or R6, or heterocyclyl comprising one or two 3- to 6-membering rings and 1 to 3 heteroatoms selected from N and O and optionally substituted with one or more hydroxy or R6;
• or two R5, together with the atom or atoms to which they are attached, form a 3- to 5-membered saturated or 5- or 6-membered aromatic ring optionally comprising 1 or 2 heteroatoms selected from N and O;
• each R6 is independently NR3C(O)R7 or C(O)NR3R7;
• each R7 is independently
• OH, (C1-C4) alkoxy, (C1-C6) alkyl optionally substituted with one or more (C1-C4) alkoxy, CF3, F, or (C3-C10) cycloalkyl,
• (C3-C10) cycloalkyl optionally substituted with one or more R8, or
• phenyl optionally substituted with one or more R8;
• each R7′ is independently H, methyl, or ethyl;
• or
• R7 and R7′, together with the atom to which they are attached, form a 3- to 6-membered ring optionally comprising one additional heteroatom selected from N and O and optionally substituted with one or more R8;
• or
• R3 and R7, together with atom(s) to which they are attached, form a 3- to 6-membered ring optionally comprising one additional heteroatom selected from N and O and optionally substituted with one or more R8;
• and
• each R8 is independently (C1-C4) alkyl, (C1-C4) alkoxy, CF3, OH, or F.